MedPath

Factor IX Complex (Human)

Generic Name
Factor IX Complex (Human)
Brand Names
Profilnine
Drug Type
Biotech
Chemical Formula
-
CAS Number
37224-63-8
Unique Ingredient Identifier
FW411QXD5M
Background

Factor IX Complex is a sterile, lyophilized concentrate composed of a number of Vitamin K-dependent clotting factors found in functioning human plasma. Also known as prothrombin complex concentrate, products containing this complex often include Factor IX (antihemophilic factor B), Factor II (prothrombin), Factor X (Stuart-Prower Factor), and low levels of Factor VII (proconvertin) derived from human plasma. Many commercially available products also contain low levels of other antithrombotic proteins. For example, Kcentra (FDA) also contains the antithrombotic proteins C and S, while Bebulin VH (FDA) contains heparin. Coagulation factors are purified from pooled human plasma and subsequently sterilized and treated.

Although Factor IX Complex products contain many different coagulation components, Factor IX is the lead component for potency and efficacy, particularly when used for the treatment of bleeding associated with Hemophilia B (Factor IX deficiency). As the product Kcentra, Factor IX Complex is also indicated for the urgent reversal of acquired coagulation factor deficiency induced by Vitamin K antagonist (VKA, e.g., warfarin) therapy in adult patients experiencing acute major bleeding or requiring rapid reversal of therapy.

Indication

Factor IX Complex is indicated for the prevention and control of hemorrhagic episodes in hemophilia B patients. It is also indicated for the urgent reversal of acquired coagulation factor deficiency induced by Vitamin K antagonist (VKA, e.g., warfarin) therapy in adult patients with acute major bleeding or who require rapid reversal of therapy.

Associated Conditions
Bleeding, Hemorrhage, Intracranial Hemorrhages
Associated Therapies
Perioperative bleeding management therapy
tribune.net.ph
·

PCC commences Phase 2 review of Mynt's acquisition of ECPay

Globe Fintech Innovations, Inc. (Mynt) plans to acquire 100% of Electronic Commerce Payments, Inc. (ECPay), prompting the Philippine Competition Commission (PCC) to initiate a Phase II review due to potential competition concerns in payment services, aggregator services, and merchant solutions. The PCC seeks public comments on the acquisition's impact on competition, quality, and service availability.
cancerletter.com
·

Jeffrey Weber on his career, mentors: “Never ever ever ever blow your cool.”

Jeffrey S. Weber was named a Fellow of the Academy of Immuno-Oncology in 2023, reflecting his significant contributions to cancer immunotherapy. He emphasized the importance of mentorship and maintaining composure, highlighting the challenges faced by early-career professionals. Weber's induction signified the respect earned from peers, a sentiment he valued highly.
newsvibesofindia.com
·

Campaigning for Phase-II ends, 239 Candidates in fray, 26 AC's, 25.78L Voters for Sep 25

Phase-II elections in Jammu and Kashmir cover 26 Assembly Constituencies across six districts, with 25.78 lakh voters and 239 candidates. Prominent figures include Omar Abdullah, Altaf Bukhari, Ravinder Raina, and Tariq Karra. Key districts are Ganderbal, Srinagar, Budgam, Reasi, Rajouri, and Poonch. Over 1.2 lakh first-time voters, 19,201 PwDs, and 20,880 voters above 85 are eligible. Polling stations are set up for smooth voting, with 3,502 stations for 26 ACs, including 157 Special polling stations.
greaterkashmir.com
·

Locked in pitched battles, BJP, Congress rope in star campaigners to gain edge in phase II

BJP and Congress deploy top campaigners for J&K assembly elections phase II and III, with PM Modi, Amit Shah, and Rahul Gandhi among key speakers.
kashmirreader.com
·

PM Modi to address BJP poll rallies in Jammu on Sept 14

PM Modi to visit Jammu on Sept 14 to address BJP election rallies. Amit Shah will also visit Rajouri and Poonch districts for rallies. BJP contests all 43 Assembly seats in Jammu division and several in Kashmir valley.
© Copyright 2025. All Rights Reserved by MedPath